4-[3-[1-[8-[4-[3-[4-[[[4-[(indan-2-yl)(propyl)amino]butyl]amino]carbonyl]-2-methoxyphenoxy]propyl]-1H-1,2,3-triazol-1-yl]octyl]-1H-1,2,3-triazol-4-yl]propoxy]-3-methoxy-N-[4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl]benzamide | 1346263-91-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 4-[3-[1-[8-[4-[3-[4-[[[4-[(indan-2-yl)(propyl)amino]butyl]amino]carbonyl]-2-methoxyphenoxy]propyl]-1H-1,2,3-triazol-1-yl]octyl]-1H-1,2,3-triazol-4-yl]propoxy]-3-methoxy-N-[4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl]benzamide
• 英文别名: 4-[3-[1-[8-[4-[3-[4-[4-[2,3-dihydro-1H-inden-2-yl(propyl)amino]butylcarbamoyl]-2-methoxyphenoxy]propyl]triazol-1-yl]octyl]triazol-4-yl]propoxy]-3-methoxy-N-[4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl]benzamide
• CAS: 1346263-91-9
• 化学式: C₆₅H₉₁N₁₁O₇
• 分子量: 1138.51
• InChiKey: PGCKDCUFJMOFOO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  10.7
• 重原子数：
  83
• 可旋转键数：
  38
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  176
• 氢给体数：
  2
• 氢受体数：
  14

反应信息

• 作为产物：
  描述：

  香草酸甲酯 在 copper(ll) sulfate pentahydrate 、 TATU 、 potassium carbonate 、 sodium ascorbate 、 N,N-二异丙基乙胺 、 potassium iodide 、 potassium hydroxide 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 39.5h， 生成 4-[3-[1-[8-[4-[3-[4-[[[4-[(indan-2-yl)(propyl)amino]butyl]amino]carbonyl]-2-methoxyphenoxy]propyl]-1H-1,2,3-triazol-1-yl]octyl]-1H-1,2,3-triazol-4-yl]propoxy]-3-methoxy-N-[4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl]benzamide
  参考文献：
  名称：

  Development of a Bivalent Dopamine D₂ Receptor Agonist

  摘要：

  Bivalent D-2 agonists may function as useful molecular probes for the discovery of novel neurological therapeutics. On the basis of our recently developed bivalent dopamine D-2 receptor antagonists of type 1, the bivalent agonist 2 was synthesized when a spacer built from 22 atoms was employed. Compared to the monovalent control compound 6 containing a capped spacer, the bis-aminoindane derivative 2 revealed substantial steepening of the competition curve, indicating a bivalent binding mode. Dimer-specific Hill slopes were not a result of varying functional properties because both the dopaminergic 2 and the monovalent control agent 6 proved to be D-2 agonists substantially inhibiting cAMP accumulation and inducing D-2 receptor internalization. Investigation of the heterobivalent ligands 8 and 9, containing an agonist and a phenylpiperazine-based antagonist pharmacophore, revealed moderate steepening of the displacement curves and antagonist to very weak partial agonist properties.

  DOI：

  10.1021/jm2009919